**Core Concept**
Nitric oxide (NO) plays a crucial role in vascular relaxation, acting as a potent vasodilator. Its release is mediated by various mechanisms, including the activation of soluble guanylyl cyclase, which increases cyclic guanosine monophosphate (cGMP) levels in smooth muscle cells. This leads to the relaxation of vascular smooth muscle, resulting in decreased blood pressure.

**Why the Correct Answer is Right**
Fenoldopam, a dopamine receptor agonist, primarily acts as a vasodilator by stimulating dopamine receptors in the renal and mesenteric blood vessels. However, its mechanism of action does not involve the release of nitric oxide (NO). Instead, fenoldopam acts directly on dopamine receptors to cause vasodilation, making it distinct from other vasodilators that rely on the NO-cGMP pathway.

**Why Each Wrong Option is Incorrect**
**Option B:** Hydralazine, a direct vasodilator, acts by releasing nitric oxide (NO) from endothelial cells, leading to the relaxation of vascular smooth muscle. Its mechanism of action involves the release of NO, making it incorrect.

**Option C:** Nitroprusside, a potent vasodilator, releases NO when it is metabolized in the bloodstream. The released NO then activates guanylyl cyclase, leading to the relaxation of vascular smooth muscle. This makes nitroprusside a NO-releasing agent, making it incorrect.

**Option D:** Nitroglycerin, a nitrate ester, releases NO when it is metabolized by the enzyme mitochondrial aldehyde dehydrogenase. The released NO then activates guanylyl cyclase, leading to the relaxation of vascular smooth muscle. This makes nitroglycerin a NO-releasing agent, making it incorrect.

**Clinical Pearl / High-Yield Fact**
Fenoldopam is unique among vasodilators in that it acts directly on dopamine receptors rather than releasing nitric oxide. This distinction is clinically relevant, as fenoldopam may be used in patients with renal artery stenosis, where the release of NO could potentially worsen renal function.

**✓ Correct Answer: A. Fenoldopam**